104
Participants
Start Date
November 30, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
May 31, 2010
Rivastigmine
Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
Placebo
Placebo, 2 times a day
Gelre Hospitals; lukas site, Apeldoorn
Medical Center Alkmaar, Alkmaar
Medical Center Leeuwarden, Leeuwarden
Erasmus Medical Center, Rotterdam
University Medical Center Utrecht, Utrecht
Diakonessenhuis, Utrecht
Collaborators (1)
ZonMw: The Netherlands Organisation for Health Research and Development
OTHER
Novartis
INDUSTRY
Netherlands Brain Foundation
OTHER
UMC Utrecht
OTHER